A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

567

Participants

Timeline

Start Date

December 6, 2017

Primary Completion Date

January 8, 2019

Study Completion Date

December 13, 2019

Conditions
Chronic Plaque PsoriasisModerate to Severe Chronic Plaque PsoriasisPsoriatic Arthritis
Interventions
DRUG

Bimekizumab

Bimekizumab will be provided at pre-specified time intervals.

DRUG

Ustekinumab

Ustekinumab will be provided as dose 1 for subjects weighing \<=100 kg and as dose 2 for subjects weighing \>100 kg at pre-specified time intervals.

OTHER

Placebo

Subjects will receive Placebo at pre-specified time points.

Trial Locations (105)

30022

Ps0009 941, Alpharetta

32174

Ps0009 921, Ormond Beach

33134

Ps0009 912, Coral Gables

33144

Ps0009 907, Miami

33437

Ps0009 909, Boynton Beach

33486

Ps0009 906, Boca Raton

33612

Ps0009 918, Tampa

34471

Ps0009 903, Ocala

46168

Ps0009 911, Plainfield

48084

Ps0009 917, Troy

50265

Ps0009 900, West Des Moines

63117

Ps0009 915, St Louis

66215

Ps0009 905, Overland Park

68144

Ps0009 958, Omaha

70809

Ps0009 922, Baton Rouge

77004

Ps0009 924, Houston

78213

Ps0009 914, San Antonio

85032

Ps0009 946, Phoenix

87106

Ps0009 923, Albuquerque

92103

Ps0009 919, San Diego

93309

Ps0009 910, Bakersfield

97210

Ps0009 920, Portland

03801

Ps0009 901, Portsmouth

08520

Ps0009 908, East Windsor

10029-65

Ps0009 913, New York

Unknown

Ps0009 004, Fremantle

Ps0009 005, Phillip

Ps0009 002, Westmead

Ps0009 009, Woolloongabba

Ps0009 050, Brussels

Ps0009 052, Liège

Ps0009 051, Loverval

Ps0009 673, Halifax

Ps0009 652, Oakville

Ps0009 651, Richmond Hill

Ps0009 650, Surrey

Ps0009 653, Toronto

Ps0009 657, Waterloo

Ps0009 218, Bonn

Ps0009 209, Darmstadt

Ps0009 214, Erlangen

Ps0009 208, Frankfurt am Main

Ps0009 210, Friedrichshafen

Ps0009 211, Hamburg

Ps0009 212, Heidelberg

Ps0009 213, Mahlow

Ps0009 205, Osnabrück

Ps0009 217, Schweinfurt

Ps0009 254, Budapest

Ps0009 255, Budapest

Ps0009 253, Orosháza

Ps0009 259, Szekszárd

Ps0009 300, Roma

Ps0009 303, Roma

Ps0009 629, Asahikawa

Ps0009 605, Bunkyō City

Ps0009 607, Chiyoda City

Ps0009 610, Chūōku

Ps0009 601, Fukuoka

Ps0009 619, Gifu

Ps0009 620, Hamamatsu

Ps0009 608, Itabashi-Ku

Ps0009 627, Itabashi-Ku

Ps0009 609, Kobe

Ps0009 600, Kurume

Ps0009 622, Matsumoto

Ps0009 604, Minatoku

Ps0009 623, Morioka

Ps0009 621, Nagoya

Ps0009 625, Nankoku

Ps0009 624, Obihiro

Ps0009 611, Osaka

Ps0009 614, Osaka

Ps0009 603, Sapporo

Ps0009 617, Sendai

Ps0009 613, Shimotsuke

Ps0009 602, Shinagawa-Ku

Ps0009 612, Shinjuku-Ku

Ps0009 618, Shinjuku-Ku

Ps0009 626, Shinjuku-Ku

Ps0009 628, Shinjuku-Ku

Ps0009 615, Sumida City

Ps0009 606, Takaoka

Ps0009 616, Tsu

Ps0009 362, Bialystok

Ps0009 369, Bialystok

Ps0009 371, Bydgoszcz

Ps0009 358, Katowice

Ps0009 357, Kielce

Ps0009 372, Lodz

Ps0009 374, Poznan

Ps0009 350, Warsaw

Ps0009 351, Warsaw

Ps0009 367, Wroclaw

Ps0009 370, Wroclaw

Ps0009 400, Moscow

Ps0009 402, Moscow

Ps0009 403, Moscow

Ps0009 404, Saint Petersburg

Ps0009 556, Cardiff

Ps0009 551, Dundee

Ps0009 553, Edgbaston

Ps0009 552, Liverpool

Ps0009 550, Manchester

Ps0009 555, Salford

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT03370133 - A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter